文献速递炎症性肠病

IBD配对:合理的联合治疗

IBD Matchmaking: Rational Combination Therapy.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-07-25

综述讨论炎症性肠病(IBD)中联合先进靶向治疗(CATT)的概念框架,介绍其他疾病联合治疗背景及IBD现有证据,并展望利用现有、新型和正交作用机制的CATT未来应用与定位。CATT旨在应对当前单一治疗疗效低和频繁失应答的问题。

要点

  • 越来越多克罗恩病和溃疡性结肠炎患者对多种先进治疗难治,需进一步治疗选择。
  • IBD中CATT知识主要限于观察性数据和早期随机对照试验。
  • 治疗暴露和疾病病程均是治疗应答的主要决定因素。

核心结论

  • CATT旨在解决当前单一治疗疗效低和频繁失应答的问题。
  • 识别安全有效的CATT可能影响该策略在更广泛IBD人群中的定位。

研究设计与样本

  • 综述,讨论IBD中CATT的概念框架、其他疾病联合治疗背景、IBD现有证据及未来应用与定位。

主要发现

  • 越来越多克罗恩病和溃疡性结肠炎患者对多种先进治疗难治、接受多次手术并需要进一步治疗选择。
  • IBD中CATT的知识主要限于观察性数据和早期随机对照试验。
  • 联合治疗在许多其他疾病中很常见。
  • 治疗暴露和疾病病程均是治疗应答的主要决定因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • IBD中CATT的知识主要限于观察性数据和早期随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A growing number of patients with Crohn's disease and ulcerative colitis have disease that is refractory to multiple advanced therapies, have undergone multiple surgeries, and require further treatment options. For this reason, there has been increasing use of multiple simultaneous advanced targeted therapies. Although the knowledge on combined advanced targeted therapy (CATT) in inflammatory bowel disease (IBD) has been largely limited to observational data and early-phase randomized controlled trials, combination of therapies is commonplace in many other diseases. This review discusses conceptual frameworks of CATT in IBD, provides context of combined therapies in other diseases, provides current evidence for CATT in IBD, and projects future applications and positioning of CATT using existing, novel, and orthogonal mechanisms of action. CATT aims to address the need to overcome low efficacy rates and frequent loss of response of current individual therapies. Both treatment exposure and disease duration are major determinants of response to therapy. Identification of safe and effective CATT may impact positioning of this strategy to apply to a broader IBD population.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Battat R, Chang JT, Loftus EV, et al. IBD Matchmaking: Rational Combination Therapy. Clin Gastroenterol Hepatol. 2024. PMID: 39025253. doi:10.1016/j.cgh.2024.05.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。